Published in final edited form as:

Nitric Oxide. 2020 February 01; 95: 12–16. doi:10.1016/j.niox.2019.12.001.

Inhaled nitric oxide use in neonates: Balancing what is evidence-based and what is physiologically sound

Laurie G. Sherlock, Clyde J. Wright, John P. Kinsella, Cassidy Delaney*

Section of Neonatology, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, 80045, USA

Abstract

Inhaled nitric oxide is a powerful therapeutic used in neonatology. Its use is evidenced-based for term and near-term infants with persistent pulmonary hypertension; however, it is frequently used off-label both in term and preterm babies. This article reviews the off-label uses of iNO in infants. Rationale is discussed for a selective application of iNO based on physiologically guided principles, and new research avenues are considered.

Keywords

Nitric oxide; Persistent pulmonary hypertension of the newborn; Pulmonary arterial hypertension; Neonate; Respiratory failure; Bronchopulmonary dysplasia

1. Review of nitric oxide and on-label use of iNO in neonates

Nitric oxide (NO) is an endogenous signaling molecule with a number of important biologic effects. One of the major roles of NO in the developing lung is regulation of pulmonary vascular tone. Key studies in the ovine model of persistent pulmonary hypertension of the newborn (PPHN) revealed that inhalation of NO (iNO) causes potent and selective pulmonary vasodilation [1]. Shortly thereafter the first reports of the use in neonates with PPHN demonstrated that iNO was associated with improvement of oxygenation with no detectable toxicity [2,3]. Numerous RCTs followed, demonstrating that iNO improves oxygenation and decreases the need for ECMO in term and near-term neonates with PPHN [4-12]. These studies led to FDA approval for the use of iNO as a pulmonary vasodilator in term and near-term (> 34 weeks' gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension. With the establishment of iNO safety and efficacy in neonates with PPHN its use in additional neonatal diseases associated with pulmonary hypertension was explored. The purpose of this review is to highlight the evidence and current practices of the off-label use of iNO in neonates.

*Corresponding author. 13243 East 23rd Avenue, Aurora, CO, 80045, USA. Cassidy.delaney@childrenscolorado.org (C. Delaney).
Author contributions

LS, CJW, CD drafted the manuscript; LS, CJW, CD and JK edited and revised manuscript.

Declaration of competing interest

The authors declare no potential financial or ethical conflicts of interest.

1.1. Off label use of iNO in infants with pulmonary hypertension associated with CDH & BPD

While the majority of neonates treated with iNO have transient pulmonary hypertension (PH) secondary to PPHN, an increasing number of infants with PH secondary to developmental lung diseases such as congenital diaphragmatic hernia (CDH) and bronchopulmonary dysplasia (BPD) receive iNO (Ref).

1.2. Congenital diaphragmatic hernia

CDH is a congenital malformation associated with high mortality and morbidity and severity of PH predicts outcome in this population of infants [13-16]. While RCTs have not demonstrated an effect on mortality or ECMO utilization with iNO use in this select population the use of iNO in neonates with CDH is widespread [5,17-19]. Hypoxemia in patients with CDH occurs secondary to both intrapulmonary shunting due to lung hypoplasia and elevation of pulmonary vascular resistance leading to extrapulmonary shunting of deoxygenated blood across the foramen ovale and patent ductus arteriosus into the systemic circulation [14]. As the physiology of this heterogeneous population of infants is complex, interpretation of each patient's unique physiology is critical to determining whether a patient may benefit from use of a potent pulmonary vasodilator such as NO. One of the key factors impacting the response of patients with CDH to pulmonary vasodilators such as iNO is the presence and degree of left ventricular dysfunction. In the setting of left ventricular dysfunction and consequent pulmonary venous hypertension the use of pulmonary vasodilators may be detrimental and lead to development of pulmonary hemorrhage [20]. The use of echocardiography in this population to guide management is essential. Reports on improved oxygenation with the combination of milrinone and iNO in infants with CDH provide support for this strategy [21]. While RCTs have not demonstrated an effect of iNO on mortality or ECMO utilization in the acute setting, PH can occur at any point in the course of an infant with CDH. iNO is associated with improvement in oxygenation in those infants who develop post-operative PH [22]. Overall the treatment strategy for patients with CDH should be tailored to each individual patient and their physiology and is too complex for this review. The reader is referred to a detailed review and expert recommendations on the use of iNO in neonates with CDH by Gien & Kinsella [23].

1.3. Bronchopulmonary dysplasia

Prospective studies show that PH develops in 14–18% of preterm infants with the chronic lung disease of prematurity, bronchopulmonary dysplasia (BPD) and contributes significantly to clinical outcomes [24,25]. Multiple pre-clinical models have demonstrated impaired NO signaling in BPD and NO administration to rodents with BPD prevents PH, improves alveolarization and has anti-inflammatory effects [26-29]. While pre-clinical evidence provides support for the use of iNO in patients with PH associated with BPD there are no RCTs evaluating the effectiveness of vasodilator therapies including iNO to treat PH in infants with BPD. Treatment of PH in these infants is based upon expert opinion and includes the optimization of gas exchange and a thorough evaluation of PH etiology including consideration of cardiac catheterization [30-33]. It is increasingly recognized that these infants may have underlying LV dysfunction, intracardiac or extracardiac shunts, PV

stenosis, or PVOD contributing to PH and initiation of a pulmonary vasodilator in these patients would be deleterious [34,35]. Literature on the use of iNO in this population is limited to reports in select patients with BPD, many of whom did not have demonstrable evidence of PH but did have an acute improvement in oxygenation [36-38]. If iNO is used in infants with established BPD and PH, given its rapid onset and issues with cost and feasibility of delivery, iNO is used primarily to treat acute PH episodes. If PH persists despite optimization of ventilation, following a thorough evaluation of PH etiology select infants may benefit from prolonged iNO as treatment with oral pulmonary vasodilators is initiated.

2. Use of iNO in preterm infants to prevent BPD

2.1. Preclinical rationale to investigate iNO to prevent bronchopulmonary dysplasia

BPD is associated with long-term pulmonary and neurodevelopmental impairment [39]. Despite advances in neonatal care, BPD is not decreasing, and incidence may be increasing in the most immature babies [40]. Preclinical data provided rationale to evaluate iNO as a potential therapeutic for the prevention of BPD. In a variety of preclinical models, iNO improves oxygenation and pulmonary vascular resistance, decreases pulmonary oxidative stress and inflammation, and improves alveolar development [26,41-44]. However, concerns exist for unintended side effects in the most vulnerable early gestational ages. iNO increases bleeding time in adults and impairs platelet aggregation in neonates, thus potentially could increase intraventricular hemorrhage (IVH) [45,46]. Additionally, the antioxidant defense system is underdeveloped in premature infants, and iNO could induce an oxidative burden by rapidly interacting with superoxide anion, creating the highly toxic prooxidant, peroxynitrite [47]. Trials in human neonates were designed to evaluate these potential benefits as well as harms.

2.2. Clinical trials in premature infants do not support use of iNO for the prevention of BPD

Multiple randomized controlled trials (RCTs) have investigated short and long-term outcomes after iNO therapy in premature infants. These studies vary significantly in the age and illness severity at randomization, maximum dose and duration of iNO prescribed, and policies defining iNO response and weaning. Perhaps not surprising in light of this heterogeneity, the results of these trials are inconsistent. Overall, they do not support the use of iNO to prevent BPD. The studies can be categorized by those evaluating early use (initiated < 3 days, either for routine prophylaxis or “rescue” of hypoxemic respiratory failure) and later/selective use (started > 4 days of life, targeting infants at higher risk for BPD).

2.3. Early iNO for the prevention of BPD

Several RCTs conducted in the USA, Canada and Europe tested the early use of iNO, initiated prior to 3 days of life in infants who were mechanically ventilated [48-52]. An initial single center trial demonstrated promising results with a reduction in death or bronchopulmonary dysplasia [52]. However, the majority of the subsequent multicenter trials did not corroborate these findings [48-51]. Subgroup analysis in some of these studies

suggested a potential benefit in the larger VLBW infants. Schreiber et al. demonstrated improved outcomes for infants > 1000g [52] and Kinsella et al. showed significant reductions in death or BPD in neonates 1000–1250g [49].

Noninvasive ventilation is increasingly used in the VLBW population, as a result of evidence that avoiding mechanical ventilation prevents BPD [53]. Kinsella et al. tested if early noninvasive iNO initiated < 3 days would prevent subsequent intubation or BPD in infants < 1250. They found no difference in the number of babies requiring mechanical ventilation or developing BPD [54].

2.4. Late iNO for the prevention of BPD

Two large multicenter trials evaluated a selective approach for iNO, by randomizing infants with a continued requirement for mechanical ventilation (MV) after 5–7 days, thus considered higher risk for BPD. There is less heterogeneity between these two trials, with relative similarities in recruited patient population, doses of inhaled nitric oxide, and specified outcome measures. Despite this, their results are inconsistent. In the NO CLD trial, 588 infants still intubated between 7 and 21 days were randomized to iNO or placebo for up to 21 days or placebo. Those treated with iNO exhibited a significant decrease in the incidence of survival without BPD [55]. In contrast, the NEWNO trial evaluated 451 infants reliant on MV between 5 and 14 days. In this study, iNO demonstrated no improvement in mortality, BPD, or other short- or long-term outcomes [56].

Multiple meta-analyses and systematic reviews have addressed the combined results of these trials. In 2011, the National Institute of Health (NIH) statement, the Johns Hopkin University Evidence-Based Practice Center, and the meta-analysis of individual patient data from 12 of these trials concluded iNO demonstrated no significant improvements in short-term or long-term outcomes in preterm infants [57–59]. In 2014, American Academy of Pediatrics (AAP) guidelines recommended against the routine use of iNO in premature babies, citing cost and insufficient evidence for benefit [60]. A recent systematic review in 2017 affirmed these findings, concluding that iNO does not prevent BPD or improve survival in premature neonates [57,61,62].

3. Why does use of iNO continue in the VLBW population?

Despite these recommendations, use of iNO in premature infants continued and even increased in some institutions [63]. There are several plausible explanations for why the utilization of iNO has increased despite multiple studies revealing no overall significant benefit in VLBW babies. VLBW infants experience hypoxemic respiratory failure primarily as a result of V/Q mismatch and intrapulmonary shunting as a result of surfactant deficiency. The contribution of PPHN to hypoxemia in this population is increasingly recognized. Inhaled nitric oxide has demonstrated ability to transiently improve oxygenation in this population, measured by partial pressure of oxygen (PaO₂) and oxygenation index (OI) [64,65]. None of the randomized controlled trials conducted in this population evaluated PPHN defined by echocardiogram, thus it can be reasonably argued until rigorously studied, a therapeutic challenge may be considered. In the setting of a profoundly hypoxemic

premature infant with lack of safe alternative therapeutic options, clinical decision making is often guided on prior experience, physiologic rationale and biologic plausibility.

This rationale guides *selective* application of iNO to individual patients based on physiologic principles [66,67]. The NIH statement and the American Thoracic Society and Pediatric PH guidelines support considering this individualized approach in specific subsets of premature patients [58,68,69]. Preterm infants with severe hypoxemia secondary to PPHN physiology, as well as those with pulmonary hypoplasia, prolonged rupture of membranes and oligohydramnios are advocated as groups to consider a trial of treatment. It is likely that recruiting enough patients in a multicenter randomized trial powered to detect meaningful outcomes is impractical given the lack of equipoise among clinicians when dealing with these critically ill babies. However, prospective data collection through the establishment of patient registries represents one option to learn more about the role of iNO in the treatment of these illnesses.

4. Is there any evidence to support off-label use of iNO in subgroups of preterm infants?

4.1. Do VLBW infants with pulmonary hypoplasia and/or PPHN benefit from iNO?

Preterm infants with pulmonary hypoplasia may have increased pulmonary vascular reactivity due to impaired angiogenesis. Several smaller case series suggested babies who experienced oligohydramnios or PROM in utero respond to iNO [70,71]. Two recent publications retrospectively evaluated a larger number of infants and are less clear regarding benefit in these groups. Chandrasekharan et al. reported a single center study comparing age-matched controls to infants treated with iNO [72]. Surviving infants treated with iNO were more frequently exposed to preterm prolonged rupture of membrane (PPROM) when compared to non-survivors. However, Ellsworth et al. evaluated iNO in a multicenter cohort study of preterm neonates with a clinical diagnosis of pulmonary hypoplasia [73]. They used a sample of 90,000 infants, of which 0.8% had a diagnosis of pulmonary hypoplasia and were included in the study. They found no statistically significant improvement in mortality, BPD, PVL or ROP in infants with pulmonary hypoplasia treated with iNO. However, these infants were identified by provider discretion, thus without established set criteria or diagnostic precision.

None of the prospective multicenter trials of iNO in premature babies required pre-randomization echocardiograms. This prohibited subgroup analysis of infants with true PPHN physiology. In Ellsworth et al., subgroup analysis compared infants with pulmonary hypoplasia with PPHN to infants *with* pulmonary hypoplasia *without* PPHN. PPHN was determined by provider discretion. They found a 33% reduced risk of in-hospital mortality (HR 0.67; 95% CI 0.45–1.01), in infants with pulmonary hypoplasia and PPHN treated with iNO [73]. Prospective study of this population is needed.

4.2. Is there a race-specific treatment effect of iNO in the preterm infant population?

Following the publication of multiple randomized controlled trials evaluating the use of iNO in premature infants, subsequent systematic reviews and individual patient data (IPD) meta-

analysis, the NIH Consensus Development Conference concluded that “taken as a whole, the available evidence does not support use of iNO in early-routine, early-rescue, or later-rescue regimens in the care of premature infants.” [58] However, the group acknowledged that *subgroup analysis were hypothesis generating and could serve as the basis for recommending future research directions*. In particular, the commissioned systematic review from The Johns Hopkins University Evidence-based Practice Center stated “there is insufficient evidence to evaluate the relationship between iNO therapy and infant sex, race/ethnic group, gestational age, or socioeconomic status” [74]. However, the MAPPiNO IPD meta-analysis showed a non-significant trend toward greater treatment effect in non-white infants [59].

Recently, Askie and colleagues have published “Race Effects of Inhaled Nitric Oxide in Preterm Infants: An Individual Participant Data Meta-Analysis” (RiNOP) [75]. The analysis was limited to three trials: the Schreiber trial [52], NOCLD [55], and the NEWNO trial [56]. The rate of death or BPD with iNO treatment in African American infants was 49%, compared to 63% in controls (RR 0.77; 95% CI, 0.65–0.91) and the authors concluded that “iNO therapy should be considered for preterm African American infants at high risk for BPD. iNO to prevent BPD in African Americans may represent an example of racially customized therapy for infants” [75].

Prior to concluding that “iNO in African Americans may represent an example of a racially customized therapy for infants,” we must acknowledge the limitation of making this conclusion based on sub-group analysis. These studies were not designed to determine the relationship between race/ethnicity and response to iNO. Infant race was determined by maternal self-report; paternal race/ethnicity was not considered. Prospective studies on the relationship between race/ethnicity and a response to therapy should have thorough descriptions of how race/ethnicity were determined and be adequately powered to interrogate this relationship across multiple groups. Of note, RiNOP found clinically significant treatment effects in other racial/ethnic groups evaluated (10% in Hispanic), although limited numbers of subjects may have precluded this finding reaching clinical significance. Furthermore, the authors of RiNOP have used maternal self-reported race/ethnicity as a proxy for the infants genetics, citing “a high concordance between genetic African ancestry and self-reported African American race [75]. However, there are significant limitations of using race as a proxy for genetic makeup [76,77]. Race is a sociologic variable and travels with a diverse set of exposures and environments. The impact of these variables on the observed treatment effect was not considered. Without a thorough understanding of the interplay of race/ethnicity and these other exposures, we risk therapeutic misuse of iNO in the preterm population [78]. Thus, while the findings of RiNOP are hypothesis-generating, further prospective, randomized clinical trials are necessary to evaluate the observed treatment effect [79].

5. Conclusion

Inhaled nitric oxide is a powerful and useful therapeutic, proven effective in term and near-term neonates with PPHN. The off-label uses of iNO for infants are primarily based on physiologically guided rationale as opposed to evidence-based medicine. Overall, trials of

iNO in VLBW infants have not shown evidence of harm, suggesting it is likely safe. Future trials prospectively randomizing infants with echocardiographic evidence of PPHN, history of oligohydramnios/pulmonary hypoplasia, or by race are needed to further guide clinical care.

Acknowledgments

Funding

This work was supported by NIH grant R01HL132941 to CJW; K08 HL132014-01 To CD.

Abbreviations:

BPD	bronchopulmonary dysplasia
HRF	hypoxemic respiratory failure
iNO	inhaled nitric oxide
IVH	intraventricular hemorrhage
OI	oxygenation index
MV	mechanical ventilation
RCTs	randomized control trials
PaO₂	partial pressure of oxygen
PPHN	persistent pulmonary hypertension of the newborn
PH	pulmonary hypertension
PAH	pulmonary arterial hypertension
VLBW	low birth weight

References

- [1]. Kinsella JP, McQueston JA, Rosenberg AA, Abman SH, Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation, *Am. J. Physiol* 263 (1992) H875–H880. [PubMed: 1415614]
- [2]. Kinsella JP, Neish SR, Shaffer E, Abman SH, Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn, *Lancet* 340 (1992) 819–820. [PubMed: 1357246]
- [3]. Roberts JD, Polaner DM, Lang P, Zapol WM, Inhaled nitric oxide in persistent pulmonary hypertension of the newborn, *Lancet* 340 (1992) 818–819. [PubMed: 1357245]
- [4]. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Mayock DE, Redding GJ, deLemos RA, Sardesai S, McCurnin DC, Moreland SG, Cutter GR, Abman SH, Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn, *J. Pediatr* 131 (1997) 55–62. [PubMed: 9255192]
- [5]. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, Kinsella JP, Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group, *N. Engl. J. Med* 342 (2000) 469–474. [PubMed: 10675427]

- [6]. Wessel DL, Adatia I, Van Marter LJ, Thompson JE, Kane JW, Stark AR, Kourembanas S, Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn, *Pediatrics* 100 (1997) E7.
- [7]. Lipkin PH, Davidson D, Spivak L, Straube R, Rhines J, Chang CT, Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide, *J. Pediatr* 140 (2002) 306–310. [PubMed: 11953727]
- [8]. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, Chang CT, Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group, *Pediatrics* 101 (1998) 325–334. [PubMed: 9480993]
- [9]. Cornfield DN, Maynard RC, deRegnier RA, Guiang SF 3rd, Barbato JE, Milla CE, Randomized, controlled trial of low-dose inhaled nitric oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension, *Pediatrics* 104 (1999) 1089–1094. [PubMed: 10545552]
- [10]. Dobyns EL, Cornfield DN, Anas NG, Fortenberry JD, Tasker RC, Lynch A, Liu P, Eells PL, Griebel J, Baier M, Kinsella JP, Abman SH, Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure, *J. Pediatr* 134 (1999) 406–412. [PubMed: 10190913]
- [11]. Neonatal G, Inhaled Nitric Oxide Study, Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure, *N. Engl. J. Med* 336 (1997) 597–604. [PubMed: 9036320]
- [12]. Barrington KJ, Finer N, Pennaforte T, Altit G, Nitric oxide for respiratory failure in infants born at or near term, *Cochrane Database Syst. Rev* 1 (2017) CD000399. [PubMed: 28056166]
- [13]. Kotecha S, Barbato A, Bush A, Claus F, Davenport M, Delacourt C, Deprest J, Eber E, Frenckner B, Greenough A, Nicholson AG, Anton-Pacheco JL, Midulla F, Congenital diaphragmatic hernia, *Eur. Respir. J* 39 (2012) 820–829. [PubMed: 22034651]
- [14]. Gien J, Kinsella JP, Differences in preductal and postductal arterial blood gas measurements in infants with severe congenital diaphragmatic hernia, *Arch. Dis. Child. Fetal Neonatal Ed* 101 (2016) F314–F318. [PubMed: 26514398]
- [15]. Grover TR, Murthy K, Brozanski B, Gien J, Rintoul N, Keene S, Najaf T, Chicoine L, Porta N, Zaniletti I, Pallotto EK, Children's Hospitals Neonatal C, Short-term outcomes and medical and surgical interventions in infants with congenital diaphragmatic hernia, *Am. J. Perinatol* 32 (2015) 1038–1044. [PubMed: 25825963]
- [16]. Wynn J, Krishnan U, Aspelund G, Zhang Y, Duong J, Stolar CJ, Hahn E, Pietsch J, Chung D, Moore D, Austin E, Mychaliska G, Gajarski R, Foong YL, Michelfelder E, Potołka D, Bucher B, Warner B, Grady M, Azarow K, Fletcher SE, Kutty S, Delaney J, Crombleholme T, Rosenzweig E, Chung W, Arkovitz MS, Outcomes of congenital diaphragmatic hernia in the modern era of management, *J. Pediatr.* 163 (2013) 114–119 e1. [PubMed: 23375362]
- [17]. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia, Neonatal. Inhaled. Oxide. Study Group. NINOS. *Pediatr.* 99 (1997) 838–845.
- [18]. Campbell BT, Herbst KW, Briden KE, Neff S, Ruscher KA, Hagadorn JI, Inhaled nitric oxide use in neonates with congenital diaphragmatic hernia, *Pediatrics* 134 (2014) e420–e426. [PubMed: 25022736]
- [19]. Putnam LR, Tsao K, Morini F, Lally PA, Miller CC, Lally KP, Harting MT, Congenital G Diaphragmatic Hernia Study, Evaluation of variability in inhaled nitric oxide use and pulmonary hypertension in patients with congenital diaphragmatic hernia, *JAMA Pediatr* 170 (2016) 1188–1194. [PubMed: 27723858]
- [20]. Kinsella JP, Steinhorn RH, Mullen MP, Hopper RK, Keller RL, Ivy DD, Austin ED, Krishnan US, Rosenzweig EB, Fineman JR, Everett AD, Hanna BD, Humpl T, Raj JU, Abman SH, Pediatric pulmonary hypertension N, the left ventricle in congenital diaphragmatic hernia: implications for the management of pulmonary hypertension, *J. Pediatr* 197 (2018) 17–22. [PubMed: 29628412]
- [21]. Kumar VHS, Dadiz R, Koumoundouros J, Guilford S, Lakshminrusimha S, Response to pulmonary vasodilators in infants with congenital diaphragmatic hernia, *Pediatr. Surg. Int* 34 (2018) 735–742. [PubMed: 29808281]

- [22]. Kinsella JP, Ivy DD, Abman SH, Pulmonary vasodilator therapy in congenital diaphragmatic hernia: acute, late, and chronic pulmonary hypertension, *Semin. Perinatol* 29 (2005) 123–128. [PubMed: 16052736]
- [23]. Gien J, Kinsella JP, Management of pulmonary hypertension in infants with congenital diaphragmatic hernia, *J. Perinatol* 36 (Suppl 2) (2016) S28–S31. [PubMed: 27225962]
- [24]. Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N, Prospective analysis of pulmonary hypertension in extremely low birth weight infants, *Pediatrics* 129 (2012) e682–e689. [PubMed: 22311993]
- [25]. Mourani PM, Sontag MK, Younoszai A, Miller JI, Kinsella JP, Baker CD, Poindexter BB, Ingram DA, Abman SH, Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia, *Am. J. Respir. Crit. Care Med* 191 (2015) 87–95. [PubMed: 25389562]
- [26]. Tourneux P, Markham N, Seedorf G, Balasubramaniam V, Abman SH, Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin-induced bronchopulmonary dysplasia in neonatal rats, *Am. J. Physiol. Lung Cell Mol. Physiol* 297 (2009) L1103–L1111. [PubMed: 19837849]
- [27]. MacRitchie AN, Albertine KH, Sun J, Lei PS, Jensen SC, Freestone AA, Clair PM, Dahl MJ, Godfrey EA, Carlton DP, Bland RD, Reduced endothelial nitric oxide synthase in lungs of chronically ventilated preterm lambs, *Am. J. Physiol. Lung Cell Mol. Physiol* 281 (2001) L1011–L1020. [PubMed: 11557605]
- [28]. Afshar S, Gibson LL, Yuhanna IS, Sherman TS, Kerecman JD, Grubb PH, Yoder BA, McCurnin DC, Shaul PW, Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease, *Am. J. Physiol. Lung Cell Mol. Physiol* 284 (2003) L749–L758. [PubMed: 12676765]
- [29]. Tang JR, Markham NE, Lin YJ, McMurtry IF, Maxey A, Kinsella JP, Abman SH, Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor, *Am. J. Physiol. Lung Cell Mol. Physiol* 287 (2004) L344–L351. [PubMed: 15064225]
- [30]. Frank BS, Schafer M, Grenolds A, Ivy DD, Abman SH, Darst JR, Acute vasoreactivity testing during cardiac catheterization of neonates with bronchopulmonary dysplasia-associated pulmonary hypertension, *J. Pediatr* 208 (2019) 127–133. [PubMed: 30871795]
- [31]. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RMF, Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management, *Eur. Respir. J* 53 (2019).
- [32]. Hansmann G, Apitz C, Abdul-Khaliq H, Alastalo TP, Beerbaum P, Bonnet D, Dubowy KO, Gorenflo M, Hager A, Hilgendorff A, Kaestner M, Koestenberger M, Koskenvuo JW, Kozlik-Feldmann R, Kuehne T, Lammers AE, Latus H, Michel-Behnke I, Miera O, Moledina S, Muthurangu V, Pattathu J, Schranz D, Warnecke G, Zartner P, Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK, *Heart* 102 (Suppl 2) (2016) ii86–100. [PubMed: 27053701]
- [33]. Abman SH, Monitoring cardiovascular function in infants with chronic lung disease of prematurity, *Arch. Dis. Child. Fetal Neonatal Ed* 87 (2002) F15–F18. [PubMed: 12091282]
- [34]. Drossner DM, Kim DW, Maher KO, Mahle WT, Pulmonary vein stenosis: prematurity and associated conditions, *Pediatrics* 122 (2008) e656–e661. [PubMed: 18762500]
- [35]. Mourani PM, Ivy DD, Rosenberg AA, Fagan TE, Abman SH, Left ventricular diastolic dysfunction in bronchopulmonary dysplasia, *J. Pediatr* 152 (2008) 291–293. [PubMed: 18206706]
- [36]. Banks BA, Seri I, Ischiropoulos H, Merrill J, Rychik J, Ballard RA, Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia, *Pediatrics* 103 (1999) 610–618. [PubMed: 10049965]
- [37]. Lonnqvist PA, Jonsson B, Winberg P, Frostell CG, Inhaled nitric oxide in infants with developing or established chronic lung disease, *Acta Paediatr.* 84 (1995) 1188–1192. [PubMed: 8563234]

- [38]. Mourani PM, Ivy DD, Gao D, Abman SH, Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia, *Am. J. Respir. Crit. Care Med* 170 (2004) 1006–1013. [PubMed: 15184202]
- [39]. Cheong JLY, Doyle LW, An update on pulmonary and neurodevelopmental outcomes of bronchopulmonary dysplasia, *Semin. Perinatol* 42 (2018) 478–484. [PubMed: 30401478]
- [40]. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, Laptook AR, Sanchez PJ, Van Meurs KP, Wyckoff M, Das A, Hale EC, Ball MB, Newman NS, Schibler K, Poindexter BB, Kennedy KA, Cotten CM, Watterberg KL, D'Angio CT, DeMauro SB, Truog WE, Devaskar U, Higgins RD, Eunice H Kennedy Shriver National Institute of Child, N. Human Development Neonatal Research, Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012, *J. Am. Med. Assoc* 314 (2015) 1039–1051.
- [41]. Bland RD, Albertine KH, Carlton DP, MacRitchie AJ, Inhaled nitric oxide effects on lung structure and function in chronically ventilated preterm lambs, *Am. J. Respir. Crit. Care Med* 172 (2005) 899–906. [PubMed: 15976381]
- [42]. Kinsella JP, Abman SH, Inhaled nitric oxide in the premature infant: animal models and clinical experience, *Semin. Perinatol* 21 (1997) 418–425. [PubMed: 9352614]
- [43]. Stenger MR, Rose MJ, Joshi MS, Rogers LK, Chicoine LG, Bauer JA, Nelin LD, Inhaled nitric oxide prevents 3-nitrotyrosine formation in the lungs of neonatal mice exposed to >95% oxygen, *Lung* 188 (2010) 217–227. [PubMed: 20237791]
- [44]. ter Horst SA, Walther FJ, Poorthuis BJ, Hiemstra PS, Wagenaar GT, Inhaled nitric oxide attenuates pulmonary inflammation and fibrin deposition and prolongs survival in neonatal hyperoxic lung injury, *Am. J. Physiol. Lung Cell Mol. Physiol* 293 (2007) L35–L44. [PubMed: 17384081]
- [45]. Hogman M, Frostell C, Arnberg H, Hedenstierna G, Bleeding time prolongation and NO inhalation, *Lancet* 341 (1993) 1664–1665.
- [46]. Cheung PY, Salas E, Etches PC, Phillipos E, Schulz R, Radomski MW, Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates, *Lancet* 351 (1998) 1181–1182.
- [47]. Aikio O, Vuopala K, Pokela ML, Andersson S, Hallman M, Nitrotyrosine and NO synthases in infants with respiratory failure: influence of inhaled NO, *Pediatr. Pulmonol* 35 (2003) 8–16. [PubMed: 12461733]
- [48]. Mercier JC, Hummler H, Durrmeyer X, Sanchez-Luna M, Carnielli V, Field D, Greenough A, Van Overmeire B, Jonsson B, Hallman M, Baldassarre J, Group ES, Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial, *Lancet* 376 (2010) 346–354. [PubMed: 20655106]
- [49]. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, Sekar KC, Auten RL, Bhutani VK, Gerdes JS, George TN, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Strain JD, Baier M, Abman SH, Early inhaled nitric oxide therapy in premature newborns with respiratory failure, *N. Engl. J. Med* 355 (2006) 354–364. [PubMed: 16870914]
- [50]. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, Perritt R, Higgins RD, Oh W, Hudak ML, Laptook AR, Shankaran S, Finer NN, Carlo WA, Kennedy KA, Fridriksson JH, Steinhorn RH, Sokol GM, Konduri GG, Aschner JL, Stoll BJ, D'Angio CT, Stevenson DK, S, Premie Inhaled Nitric Oxide, Inhaled nitric oxide for premature infants with severe respiratory failure, *N. Engl. J. Med* 353 (2005) 13–22. [PubMed: 16000352]
- [51]. Hascoet JM, Fresson J, Claris O, Hamon I, Lombet J, Liska A, Cantagrel S, Al Hosri J, Thiriez G, Valdes V, Vittu G, Egretteau L, Henrot A, Buchweiller MC, Onody P, The safety and efficacy of nitric oxide therapy in premature infants, *J. Pediatr* 146 (2005) 318–323. [PubMed: 15756211]
- [52]. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P, Inhaled nitric oxide in premature infants with the respiratory distress syndrome, *N. Engl. J. Med* 349 (2003) 2099–2107. [PubMed: 14645637]
- [53]. Wright CJ, Polin RA, Kirpalani H, Continuous positive airway pressure to prevent neonatal lung injury: how did we get here, and how do we improve? *J. Pediatr* 173 (2016) 17–24 e2. [PubMed: 27025910]

- [54]. Kinsella JP, Cutter GR, Steinhorn RH, Nelin LD, Walsh WF, Finer NN, Abman SH, Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns, J. Pediatr 165 (2014) 1104–1108 e1. [PubMed: 25063725]
- [55]. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombok SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE, Group NCS, Inhaled nitric oxide in preterm infants undergoing mechanical ventilation, N. Engl. J. Med. 355 (2006) 343–353. [PubMed: 16870913]
- [56]. Hasan SU, Potenziano J, Konduri GG, Perez JA, Van Meurs KP, Walker MW, Yoder BA, Newborns G, Treated with nitric oxide trial, effect of inhaled nitric oxide on survival without bronchopulmonary dysplasia in preterm infants: a randomized clinical trial, JAMA Pediatr 171 (2017) 1081–1089. [PubMed: 28973344]
- [57]. Donohue PK, Gilmore MM, Cristofalo E, Wilson RF, Weiner JZ, Lau BD, Robinson KA, Allen MC, Inhaled nitric oxide in preterm infants: a systematic review, Pediatrics 127 (2011) e414–e422. [PubMed: 21220391]
- [58]. Cole FS, Alleyne C, Barks JD, Boyle RJ, Carroll JL, Dokken D, Edwards WH, Georgieff M, Gregory K, Johnston MV, Kramer M, Mitchell C, Neu J, Pursley DM, Robinson WM, Rowitch DH, NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants, Pediatrics 127 (2011) 363–369. [PubMed: 21220405]
- [59]. Askie LM, Ballard RA, Cutter GR, Dani C, Elbourne D, Field D, Hascoet JM, Hibbs AM, Kinsella JP, Mercier JC, Rich W, Schreiber MD, Wongsiridej PS, Subhedar NV, Van Meurs KP, Voysey M, Barrington K, Ehrenkranz RA, Finer NN, C, Meta-analysis of Preterm Patients on Inhaled Nitric Oxide, Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials, Pediatrics 128 (2011) 729–739. [PubMed: 21930540]
- [60]. Kumar P, Committee on F, Newborn P American Academy of, Use of inhaled nitric oxide in preterm infants, Pediatrics 133 (2014) 164–170. [PubMed: 24379225]
- [61]. Askie LM, Ballard RA, Cutter G, Dani C, Elbourne D, Field D, Hascoet JM, Hibbs AM, Kinsella JP, Mercier JC, Rich W, Schreiber MD, Srisuparp P, Subhedar NV, Van Meurs KP, Voysey M, Barrington K, Ehrenkranz RA, Finer N, Meta-Analysis C of Preterm Patients on inhaled Nitric Oxide, Inhaled nitric oxide in preterm infants: a systematic review and individual patient data meta-analysis, BMC Pediatr. 10 (2010) 15. [PubMed: 20331899]
- [62]. Barrington KJ, Finer N, Pennaforte T, Inhaled nitric oxide for respiratory failure in preterm infants, Cochrane Database Syst. Rev 1 (2017) CD000509. [PubMed: 28045472]
- [63]. Clark RH, Ursprung RL, Walker MW, Ellsbury DL, Spitzer AR, The changing pattern of inhaled nitric oxide use in the neonatal intensive care unit, J. Perinatol 30 (2010) 800–804. [PubMed: 20237489]
- [64]. Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, Sardesai S, Walsh-Sukys MC, McCaffrey MJ, Cornfield DN, Bhutani VK, Cutter GR, Baier M, Abman SH, Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial, Lancet 354 (1999) 1061–1065. [PubMed: 10509496]
- [65]. Subhedar NV, Shaw NJ, Changes in oxygenation and pulmonary haemodynamics in preterm infants treated with inhaled nitric oxide, Arch. Dis. Child. Fetal Neonatal Ed 77 (1997) F191–F197. [PubMed: 9462188]
- [66]. Finer NN, Inhaled nitric oxide for preterm infants: a therapy in search of an indication? The search continues, J. Pediatr 146 (2005) 301–303. [PubMed: 15756205]
- [67]. Finer NN, Evans N, Inhaled nitric oxide for the preterm infant: evidence versus practice, Pediatrics 135 (2015) 754–756. [PubMed: 25755239]
- [68]. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Thebaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL, American CCP Heart Association Council on Cardiopulmonary, C. Resuscitation, Y. Council on Clinical, Council on cardiovascular disease in the, R. Council on cardiovascular, intervention, S. Council on cardiovascular, anesthesia, S. The American thoracic, pediatric pulmonary hypertension: guidelines from the American heart

association and American thoracic society, *Circulation* 132 (2015) 2037–2099. [PubMed: 26534956]

- [69]. Kinsella JP, Steinhorn RH, Krishnan US, Feinstein JA, Adatia I, Austin ED, Rosenzweig EB, Everett AD, Fineman JR, Hanna BD, Hopper RK, Humpl T, Ivy DD, Keller RL, Mullen MP, Raj JU, Wessel DL, Abman SH, Recommendations for the use of inhaled nitric oxide therapy in premature newborns with severe pulmonary hypertension, *J. Pediatr* 170 (2016) 312–314. [PubMed: 26703869]
- [70]. Uga N, Ishii T, Kawase Y, Arai H, Tada H, Nitric oxide inhalation therapy in very low-birthweight infants with hypoplastic lung due to oligohydramnios, *Pediatr. Int* 46 (2004) 10–14. [PubMed: 15043657]
- [71]. Semberova J, O'Donnell SM, Franta J, Miletin J, Inhaled nitric oxide in preterm infants with prolonged preterm rupture of the membranes: a case series, *J. Perinatol* 35 (2015) 304–306. [PubMed: 25813677]
- [72]. Chandrasekharan P, Kozielski R, Kumar VH, Rawat M, Manja V, Ma C, Lakshminrusimha S, Early use of inhaled nitric oxide in preterm infants: is there a rationale for selective approach? *Am. J. Perinatol* 34 (2017) 428–440. [PubMed: 27627792]
- [73]. Ellsworth KR, Ellsworth MA, Weaver AL, Mara KC, Clark RH, Carey WA, Association of early inhaled nitric oxide with the survival of preterm neonates with pulmonary hypoplasia, *JAMA Pediatr* 172 (2018) e180761. [PubMed: 29800952]
- [74]. Allen MC, Donohue P, Gilmore M, Cristofalo E, Wilson RF, Weiner JZ, Robinson K, Inhaled nitric oxide in preterm infants, *Evid. Rep. Technol. Assess* (2010) 1–315.
- [75]. Askie LM, Davies LC, Schreiber MD, Hibbs AM, Ballard PL, Ballard RA, Race effects of inhaled nitric oxide in preterm infants: an individual participant data meta-analysis, *J. Pediatr* 193 (2018) 34–39 e2. [PubMed: 29241680]
- [76]. Foster MW, Sharp RR, Beyond race: towards a whole-genome perspective on human populations and genetic variation, *Nat. Rev. Genet.* 5 (2004) 790–796. [PubMed: 15510170]
- [77]. Collins FS, What we do and don't know about 'race', 'ethnicity', genetics and health at the dawn of the genome era, *Nat. Genet* 36 (2004) S13–S15. [PubMed: 15507997]
- [78]. Hwang SS, Burris HH, Collins JW Jr., Kirpalani H, Wright CJ, Moving beyond race and ethnicity to understand the effect of inhaled nitric oxide on bronchopulmonary dysplasia prevention, *J. Pediatr* 201 (2018) 298–300.
- [79]. Foglia EE, DeMauro SB, Dysart K, Kirpalani H, When has enough evidence accumulated to change neonatal practice? *Semin. Fetal Neonatal Med* 20 (2015) 424–430. [PubMed: 26441032]